Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of <i>in vivo</i> immunomodulation

Matthew Streetly, Stephen Schey, Kylie Gyertson et al.|British Journal of Haematology|2008

Cited by 127